ストックスクリーナーアプリを入手
0.825
3.00%
-0.0255
アフターアワーズ：
.87
0.045
+5.45%
前日終値:
$0.8505
開ける：
$0.86
24時間の取引高:
32,489
Relative Volume:
0.29
時価総額：
$10.83M
収益：
$52.16M
当期純損益:
$-48.60M
株価収益率:
-0.191
EPS:
-4.32
ネットキャッシュフロー:
$-77.48M
1週間 パフォーマンス:
-30.08%
1か月 パフォーマンス:
-40.65%
6か月 パフォーマンス:
-79.63%
1年 パフォーマンス:
-88.96%
1日の値動き範囲:
$0.8249
$0.899
1週間の範囲:
$0.8151
$1.17
52週間の値動き範囲:
$0.8151
$10.50
Hookipa Pharma Inc Stock (HOOK) Company Profile
名前
Hookipa Pharma Inc
セクター
電話
0114318906360
住所
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
HOOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
0.825 | 10.83M | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-15 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-11-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-03 | 開始されました | Truist | Buy |
| 2020-10-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-19 | 再開されました | H.C. Wainwright | Buy |
| 2019-09-27 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-13 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Hookipa Pharma Inc (HOOK) 最新ニュース
Hookipa Pharma stock plunges to 52-week low of $1.11 amid steep decline By Investing.com - Investing.com South Africa
Hookipa Pharma stock plunges to 52-week low of $1.11 amid steep decline - Investing.com India
Hookipa Pharma (HOOK) Expected to Announce Quarterly Earnings on Friday - Defense World
HOOKIPA Pharma to participate in upcoming investor conferences in September - MarketScreener
Hookipa Pharma (HOOK) Expected to Announce Earnings on Thursday - Defense World
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline - Investing.com Australia
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline By Investing.com - Investing.com South Africa
HOOKIPA Pharma Inc. SEC 10-K Report - TradingView
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn - Investing.com India
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn By Investing.com - Investing.com South Africa
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
BRIEF—Proposed combination of Poolbeg with HOOKIPA called off - The Pharma Letter
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma By Investing.com - Investing.com Australia
Poolbeg slumps as Hookipa merger is called off - pharmaphorum
Hookipa Pharma (NASDAQ:HOOK) Shares Down 4.8% – Time to Sell? - Defense World
Poolbeg Pharma PLC (AIM:POLB) Termination of proposed combination with HOOKIPA - Share Talk
Poolbeg merger off after HOOKIPA ends discussions - Proactive Investors
Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger - TradingView
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) - GlobeNewswire
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma - Investing.com India
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - StockTitan
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn - MSN
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance
Hookipa Pharma Files Petition to Validate Stockholder Actions at Annual Meetings - Defense World
HOOKIPA completes enrollment for HIV vaccine trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma seeks court validation for stockholder actions By Investing.com - Investing.com Australia
HOOKIPA completes enrollment for HIV vaccine trial - Investing.com India
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire
Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - StockTitan
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment… - Informazione.it
Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma Deal - MarketWatch
Poolbeg Pharma granted extension to PUSU Deadline - DirectorsTalk Interviews
Poolbeg and HOOKIPA given more time to agree merger deal - Proactive Investors USA
Poolbeg Pharma PLC (AIM:POLB) Offer Update – Extension to PUSU Deadline - Share Talk
Poolbeg Pharma and HOOKIPA Extend Merger Deadline Amid Positive Discussions - TipRanks
HOOKIPA Pharma seeks court validation for stockholder actions - MSN
Hookipa Pharma Seeks Validation for Stockholder Meetings - TipRanks
HOOK (HOOKIPA Pharma) Shares Outstanding (EOP) : 12.05 Mil (As of Sep. 2024) - GuruFocus.com
Hookipa Pharma stock hits 52-week low at $1.73 amid market challenges - Investing.com Nigeria
Hookipa Pharma Inc (HOOK) 財務データ
収益
当期純利益
現金流量
EPS
10.70%
大文字化:
|
ボリューム (24 時間):